267 million

Since its launch in 2000, GAVI support has resulted in the immunisation of 267 million children with the hepatitis B vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

91 million

Since its launch in 2000, GAVI support has resulted in the immunisation of 91 million children with the Haemophilus influenzae type b vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

76.5 million

Since its launch in 2000, GAVI support has resulted in the immunisation of 76.5 million children with the DTP3 vaccine (diphtheria, tetanus, pertussis).

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

706,000

Since 2009, GAVI support has resulted in the immunisation of 706,000 children with the pneumococcal vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

933,000

Since 2007, GAVI support has resulted in the immunisation of 933,000 children with the rotavirus vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

US$5.9 billion

GAVI has committed US$ 5.9 billion in programme support to low-income countries until 2015.

Source: GAVI Alliance data November 2010

36%

Pneumonia and diarrhoea together account for 36% of child deaths in low-income countries.

Source: WHO, World Health Statistics 2010

US$750 million

The Bill & Melinda Gates Foundation gave GAVI a start-up grant of US$ 750 million in 1999.

Source: GAVI Alliance data 2010

267 million

Since its launch in 2000, GAVI support has resulted in the immunisation of 267 million children with the hepatitis B vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

68%

Hepatitis B vaccine coverage has risen to 68% in low-income countries compared with 17% in 2000.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

79%

DTP3 coverage – three doses of diptheria, tentanus and pertussis – in low-income countries has increased from 66% in 2000 to 79% in 2010 – its highest level ever.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

MDG4

With full funding, GAVI support for increased immunisation will make significant contributions to achieving Millennium Development Goal 4 to reduce child mortality.

Source: GAVI business plan 2010

230 million

If fully funded, GAVI will roll out the 5-in-1 pentavalent vaccine to 230 million additional children through to 2015.

Source: GAVI business plan 2010

53 million

With full funding through to 2015, GAVI support will result in the immunisation of 53 million additional children with rotavirus vaccine, the leading cause of diarrhoea.

Source: GAVI business plan 2010

90 million

If fully funded, GAVI support will result in the immunisation of 90 million additional children against pneumococcal disease (the leading cause of pneumonia) from 2011 to 2015.

Source: GAVI business plan 2010

243 million

With full funding through to 2015, GAVI support will result in the immunisation of 243 million additional children.

Source: GAVI business plan 2010

3.9 million

If fully funded through to 2015, GAVI’s support for vaccines, including pneumococcal disease and rotavirus, could avert an additional 3.9 million future deaths.

Source: GAVI business plan 2010

474,000

GAVI’s support for pertussis vaccine has averted 474,000 future deaths from 2000 to 2010.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

140,000

GAVI’s support for yellow fever vaccine has averted 140,000 future deaths from 2000 to 2010.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

560,000

GAVI’s support for Haemophilus influenzae type b vaccine has averted 560,000 future deaths from 2000-2010.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

1.2 million

GAVI’s support for measles vaccine has averted 1,200,000 future deaths from 2000 to 2010.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

US$20 million

GAVI is investing US$20 million in civil society organisations in developing countries through to 2015.

Source: GAVI Alliance data 2010

288 million

Since its launch in 2000, GAVI support has resulted in the immunisation of an additional 288 million children in the poorest countries.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

7 million

Providing life-saving vaccines against pneumonia and diarrhoea in 40 low-income countries will avert up to seven million future deaths by 2030.

Source: GAVI Alliance data 2010

23.2 million

Over 23 million children, aged under five, remain unimmunised in the world.

Source: WHO/UNICEF coverage estimates 1980-2009, July 2010

43 %

Forty-three percent of GAVI vaccines are produced by pharmaceutical companies based in emerging markets.

Source: GAVI Alliance data 2008

2 million

Nearly two million children die from vaccine-preventable diseases every year.

Source: WHO

16 seconds

One child dies from a vaccine-preventable disease every 16 seconds.

Source: WHO

3.4 million

GAVI’s support for hepatitis B vaccine has averted 3,407,000 future deaths from 2000 to 2010

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

5 million

In its first decade,  GAVI support to countries has averted more than five million future deaths.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010